A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy.

Paolo Angelo CortesiCarla FornariPaolo GisondiFlorenzo IannoneIppazio Cosimo AntonazzoElisabetta AloisiMartina FiocchiDaniela RitrovatoLorenzo Giovanni Mantovani

Published in: PharmacoEconomics - open (2023)

This BIA accounted for the new indication of secukinumab in nr-axSpA patients, reporting no significant changes in the required budget and adding an effective treatment option. Considering all indications, secukinumab is a sustainable treatment option.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
disease activity
newly diagnosed
combination therapy
systemic lupus erythematosus
chronic kidney disease
replacement therapy